Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer



      In advanced cancer, although performance status (PS), systemic inflammatory response and nutritional status are known to have prognostic value, geographical variations and sociodemographic indexes may also impact survival.


      This study compares validated prognostic factors in two international cohorts and establishes a prognostic framework for treatment.


      Two international biobanks of patients (n=1.518) with advanced cancer were analyzed. Prognostic factors (Eastern Cooperative Oncology Group Performance Status [ECOG-PS], body mass index [BMI] and modified Glasgow Prognostic Score [mGPS]) were assessed. The relationship between these and survival was examined using Kaplan–Meier and Cox regression methods.


      According to multivariate analysis, in the European cohort the most highly predictive factors were BMI <20 kg/m2 (hazard ratio [HR] 1.644), BMI 20-21.9 kg/m2 (HR 1.347), ECOG-PS (HR 1.597–11.992) and mGPS (HR 1.843–2.365). In the Brazilian cohort, the most highly predictive factors were ECOG-PS (HR 1.678–8.938) and mGPS (HR 2.103–2.837). Considering gastrointestinal cancers in particular (n=551), the survival rate at 3 months in both cohorts together ranged from 93% (mGPS 0, PS 0–1) to 0% (mGPS 2, PS 4), and from 81% (mGPS 0, BMI >28 kg/m2) to 44% (mGPS 2, BMI <20 kg/m2).


      The established prognostic factors that were compared had similar prognostic capacity in both cohorts. A high ECOG-PS and a high mGPS as outlined in the ECOG-PS/mGPS framework were consistently associated with poorer survival of patients with advanced cancer in the prospective European and Brazilian cohorts.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pain and Symptom Management
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Simmons CPL
        • McMillan DC
        • McWilliams K
        • et al.
        Prognostic tools in patients with advanced cancer: a systematic review.
        J Pain Symptom Manage. 2017; 53: 962-970
        • Laird BJ
        • Kaasa S
        • McMillan DC
        • et al.
        Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system.
        Clin Cancer Res. 2013; 19: 5456-5464
        • Simmons CPL
        • McMillan DC
        • Tuck S
        • et al.
        “How long have I got?”-A prospective cohort study comparing validated prognostic factors for use in patients with advanced cancer.
        The Oncologist. 2019; 24: 960-967
        • McMillan DC.
        The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer.
        Cancer Treat Rev. 2013; 39: 534-540
        • Bozzetti F
        • Santarpia L
        • Pironi L
        • et al.
        The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients.
        Annals of Oncology. 2014; 25: 487-493
        • Abbass T
        • Dolan RD
        • Laird BJ
        • McMillan DC.
        The relationship between imaging-based body composition analysis and the systemic inflammatory response in patients with cancer: a systematic review.
        Cancers. 2019; 11: 1304
        • Dolan RD
        • McSorley ST
        • Horgan PG
        • Laird BJ
        • McMillan DC.
        The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis.
        Crit Rev Oncol Hematol. 2017; 116: 134-146
        • Weaver AJ
        • Stafford R
        • Hale J
        • et al.
        Geographical and temporal variation in the incidence and mortality of hepato e pancreato e biliary primary malignancies:1990-2017.
        J Surg Res. 2020; 245: 89-98
        • Arnold M
        • Abnet CC
        • Neale RE
        • et al.
        Global burden of 5 major types of gastrointestinal cancer.
        Gastroenterology. 2020; 159: 335-349
        • Dolan RD
        • Daly LE
        • Simmons CP
        • et al.
        The relationship between ECOG-PS, mGPS, BMI/WL grade and body composition and physical function in patients with advanced cancer.
        Cancers. 2020; 12: 1187
        • Dolan RD
        • Daly L
        • Sim WMJ
        • et al.
        Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: implications for a clinically important framework in the assessment and treatment of advanced cancer.
        Clinical nutrition. 2020; 39: 2889-2895
        • von Elm E
        • Altman DG
        • Egger M
        • et al.
        The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies.
        Lancet. 2007; 370: 1453-1457
        • Martin L
        • Senesse P
        • Gioulbasanis I
        • et al.
        Diagnostic criteria for the classification of cancer-associated weight Loss.
        J Clin Oncol. 2014; 33: 90-99
        • McMillan DC.
        An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.
        Proc Nutr Soc. 2008; 67: 257-262
        • Fearon KC
        • Voss AC
        • Hustead DS.
        Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis.
        Am J Clin Nutr. 2006; 83: 1345-1350
        • Vanhoutte G
        • van de Wiel M
        • Wouters K
        • et al.
        Cachexia in cancer: what is in the definition?.
        BMJ Open Gastroenterol. 2016; 3: 97
        • Cederholm T
        • Jensen GL
        • Correia M
        • et al.
        GLIM criteria for the diagnosis of malnutrition - a consensus report from the global clinical nutrition community.
        Clin Nutr. 2019; 38: 1-9
        • Martin L
        • Muscaritoli M
        • Bourdel-Marchasson I
        • et al.
        Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis.
        J Cachexia Sarcopenia Muscle. 2021; 12: 1189-1202
        • Swetz KM
        • Smith TJ.
        Palliative chemotherapy: when is it worth it and when is it not?.
        Cancer J. 2010; 16: 467-472